Openbookopenbook
Equity
Shenzhen Hepalink Pharmaceutical Group Co. Ltd(SHEZF)
USD --+0.00%
Reward58Moderate
Risk24Low
📊75%Data
53.2% dividend yield · Revenue growing 12% YoY
SHEZF
+0.0 · +0.00%
USD · PINK
Shenzhen Hepalink Pharmaceutical Group Co. Ltd | Healthcare
Dividend King
Market Cap:689.04M
ℹ️
Reward Rating
58
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
24
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SHEZF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Shenzhen Hepalink Pharmaceutical Group Co. Ltd?

provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally.

SHEZF · Verdict

Solid reward · low risk

SHEZF scores well on cash flow and volatility with no major weaknesses flagged in the model.

Based on 88% data coverage

SHEZF · Verdict

What’s working & what to watch

Strengths 4

  • Cash flow80/100

    38% free-cash-flow margin

  • Volatility80/100

    Top decile vs peers

  • Balance sheet78/100

    Interest covered 6.1×

  • Growth65/100

    Rev -6.0% CAGR · earnings +39.0%

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Shenzhen Hepalink Pharmaceutical Group Co. Ltd?

provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 689.04M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (58)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap689.04M
P/E RatioN/A
Dividend Yield53.24%
52 Week High0.4696
52 Week Low0.4028
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding220M
No. of Employees1,926
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta0.486
CurrencyUSD · Reports in CNY
Websitewww.hepalink.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.